Companies · BDX
Becton Dickinson
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Nov 5, 2026
BD closes FY2026 with $5.3B Q4 revenue, +5.6%, as GLP-1 biologics and PureWick drive broad-based growth; FY2027 guide embeds Alaris headwind, not tariff upside
Becton Dickinson delivered Q4 FY2026 revenue of $5.3 billion, up 5.6% FX-neutral, with adjusted EPS of $4.15 — up 27.3% and ahead of expectations — driven by double-digit growth in Advanced Patient Monitoring, PureWick, biologic drug delivery, and Rowa pharmacy automation. The company completed the spin-off of its life sciences segment, fully pivoting to a pure-play medtech model, and secured a U.S. government partnership committing $19 billion in domestic investment over several years in exchange for future Section 232 tariff relief — relief that is excluded from FY2027 guidance and represents a material upside option. FY2027 guidance of low single-digit reported growth (mid-single-digit ex-Alaris) and roughly flat operating margins reflects a deliberate conservatism that management frames as executable with upside, with the Alaris comparison drag fully dissipating in FY2028.
Tone: bullishRevenue
$21.8B
BDX 10-K · FY 2025
Employees
72,000
Revenue FY2024
$20.2B
Founded
1897
Profile
BDX 10-K Item 1 · Nov 25, 2025Becton, Dickinson and Company (BD) is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. It serves healthcare institutions, physicians, life science researchers, clinical laboratories, and pharmaceutical companies worldwide. Its operations are organized into three business segments: BD Medical, BD Life Sciences, and BD Interventional.
Read filing description ↓ Collapse description ↑
BD is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. We provide customer solutions that are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology care; enhancing the diagnosis of infectious diseases and cancers; and advancing cellular research and applications. BD Medical produces a broad array of medical technologies and devices used to help improve healthcare delivery in a wide range of settings. BD Life Sciences provides products for the safe collection and transport of diagnostic specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers, as well as research and clinical tools that facilitate the study of cells. BD Interventional provides vascular, urology, oncology and surgical specialty products that are intended to be used once and then discarded or are either temporarily or permanently implanted. Effective October 1, 2025, BD reorganized into five distinct, separately-managed segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences.
Primary products
- Peripheral intravenous catheters
- Advanced peripheral catheters
- Central lines
- Vascular access technology
- Needle-free IV connectors and extension sets
- Closed-system drug transfer devices
Business segments
End markets
Geographies
Named customers
Named competitors
“BD competes in this evolving marketplace on the basis of many factors, including price, quality, innovation, service, reputation, distribution and promotion.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
BD's revenues increased from $20,178 million in fiscal year 2024 to $21,840 million in fiscal year 2025, reflecting in part the full-year contribution from the Advanced Patient Monitoring acquisition completed September 3, 2024.
The rest of BDX is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.